Practical issues on the use of enoxaparin in elective and emergent percutaneous coronary intervention

Journal of Invasive Cardiology

Volumn 20, Issue 9, 2008, Pages 482-489

  Díez, José G ^a  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEATH; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMERGENCY CARE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEMATOMA; HUMAN; MONOTHERAPY; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ENOXAPARIN; HEMORRHAGE; HEPARIN; HUMANS; INFUSIONS, INTRAVENOUS; RISK FACTORS;

EID: 50849087659     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):188S-203S.
2. Lincoff AM, Bittl JA, Harrington RA, et al; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-863.
3. Mehta SR, Steg PG, Granger CB, et al.; ASPIRE Investigators. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: A randomized evaluation (ASPIRE) pilot trial. Circulation 2005;111:1390-1397.
4. Montalescot G, White HD, Gallo R, et al; STEEPLE Investigators. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006;355:1006-1017.
5. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: A systematic overview. JAMA 2004;292:89-96.
6. White HD, Kleiman NS, Mahaffey KW, et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J 2006;152:1042-1050.
7. Antman EM, Morrow DA, McCabe CH, et al; ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006;354:1477-1488.
8. Choussat R, Montalescot G, Collet JP, et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol 2002;40:1943-1950.
9. Kereiakes DJ, Grines C, Fry E, et al; NICE 1 and NICE 4 Investigators. National Investigators Collaborating on Enoxaparin. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001;13:272-278.
10. Chen WH, Lau CP, Lau YK, et al. Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention. J Invasive Cardiol 2002;14:439-442.
11. Miller L, Gupta A, Bertolet BD. Use of clopidogrel loading, enoxaparin, and double-bolus eptifibatide in the setting of early percutaneous coronary intervention for acute coronary syndromes. J Invasive Cardiol 2002;14:247-250.
12. Díez JG, Lievano MJ, Olaya CA, et al. Enoxaparin anticoagulation for percutaneous coronary interventions: A pilot safety study. Circulation 1999;100:968.
13. Rabah MM, Premmereur J, Graham M, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999;84:1391-1395.
14. Drozd J, Opalifska E, Wójcik J, Madejczyk A. The use of enoxaparin during percutaneous coronary angioplasty in patients with stable angina. Kardiol Pol 2001;55:520-524.
15. Dudek D, Dabrowski M, Ochala A, et al. Multicenter, prospective, double-blind randomized comparison of enoxaparin versus unfractionated heparin for percutaneous coronary interventions. Am J Cardiol 2000;86(8 Suppl 1):15i, Abstract TCT-34.
16. Bhatt DL, Lee BI, Casterella PJ, et al. Coronary revascularization using integrilin and single bolus enoxaparin study. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: Results of the coronary revascularization using integrilin and single bolus enoxaparin study. J Am Coll Cardiol 2003;41:20-25.
17. Galeote G, Hussein M, Sobrino N, et al. Combination abciximab and enoxaparin or unfractionated heparin during percutaneous coronary intervention: A randomized study. Eur Heart J 2001;22( Suppl):663.
18. Madan M, Radhakrishnan S, Reis M, et al. Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial). Am J Cardiol 2005;95:1295-1301.
19. Borentain M, Montalescot G, Bouzamondo A, et al. Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: A combined analysis. Catheter Cardiovasc Interv 2005;65:212-221.
20. Montalescot G, White HD, Gallo R, et al; on behalf of the STEEPLE Investigators. Safety and efficacy of intravenous enoxaparin in elective PCI: An international randomized evaluation. One year follow up. Presented at the European Society of Cardiology (ESC) Congress 2007, Vienna, Austria, 2 September.
21. Yusuf S, Mehta SR, Chrolavicius S, et al; Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354:1464-1476.
22. Dumaine R, Borentain M, Bertel O, et al. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention-Quantitative review of randomized trials. Arch Intern Med 2007;167:2423-2430.
23. Montalescot G, Collet JP, Tanguy ML, et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004;110:392-398.
24. Gilchrist IC, Berkowitz SD, Thompson TD, et al. Heparin dosing and outcome in acute coronary syndromes: The GUSTO-IIb experience. Global Use of Strategies to Open Occluded Coronary Arteries. Am Heart J 2002;144:73-80.
25. Zalc S, Lemos PA, Esteves A, et al. Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin. J Invasive Cardiol 2006;18:45-48.
26. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention - Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:156-175.
27. Galli A, Palatnik A. What is the proper activated clotting time (ACT) at which to remove a femoral sheath after PCI? What are the best "protocols" for sheath removal? Crit Care Nurse 2005;25:88-92, 94-95.
28. Niederstadt JA. Frequency and timing of activated clotting time levels for sheath removal. J Nurs Care Qual 2004;19:34-38.
29. Juran NB, Rouse CL, Smith DD, et al. Nursing interventions to decrease bleeding at the femoral access site after percutaneous coronary intervention. SANDBAG Nursing Coordinators. Standards of Angioplasty Nursing techniques to Diminish Bleeding Around the Groin. Am J Crit Care 1999;8:303-313.
30. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-663.
31. Martin JL, Fry ET, Sanderink GJ, et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv 2004;61:163-170.
32. Moliterno DJ, Hermiller JB, Kereiakes DJ, et al; ELECT Investigators. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. J Am Coll Cardiol 2003;42:1132-1139.
33. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI 11A. J Am Coll Cardiol 1997;29:1474-1482.
34. Díez JG, Cheong BY, O'Meallie LP, Alt EU. Monitoring of enoxaparin level using citrated clotting time during percutaneous coronary intervention. J Intervent Cardiol 2004;17:307-313.
35. Cheong B, O'Meallie L, Díez JG. Enoxaparin in percutaneous interventions: When to monitor? A case series. J Invasive Cardiol 2003;15:(Suppl)1-6.
36. Levine GN, Ferrando T. Degree of anticoagulation after one subcutaneous and one subsequent intravenous booster dose of enoxaparin: Implications for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. J Thromb Thrombolysis 2004;17:167-171.
37. Aslam MS, Sundberg S, Sabri MN, et al. Pharmacokinetics of intravenous/subcutaneous enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. Catheter Cardiovasc Interv 2002;57:187-190.
38. Sanchez-Pena P, Hulot JS, Urien S, et al. Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: A population model analysis. Br J Clin Pharmacol 2005;60:364-373.
39. sanofi-aventis US. Lovenox® (enoxaparin sodium injection) product information, 2007. Available: http://products.sanofi-aventis.us/lovenox/lovenox. pdf. Accessed December 11, 2007.
40. Popma JJ, Berger P, Ohman EM, et al. Antithrombotic therapy during percutaneous coronary intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):576S-599S.
41. Ferguson JJ, Califf RM, Antman EM, et al.; SYNERGY Trial Investigators. Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: Primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54.
42. Cohen M, Mahaffey KW, Pieper K, et al.; SYNERGY Trial Investigators. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: Enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2006;48:1346-1354.
43. Gibson CM, Murphy SA, Montalescot G, et al.; ExTRACT-TIMI 25 Investigators. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 2007;49:2238-2246.